Get the detailed impact analysis of COVID-19 that has disrupted the entire world and affected many industries.
Request Insights
IN THE NEWSJuly 2020: Microba, an Australian microbial genetics firm, announced that it has strategically collaborated with Synlab, a German medical diagnostic services provider, to launch gut microbiome test across Latin America and Europe.
January 2020: The government of Canada along with other partners invested USD 18 million for the research and development of microbiome therapeutics.
The global gut microbiota market is expected to register a high CAGR of ~23% during the forecast period, i.e., 2022-2030. Extensive research associated with human gut microbiome therapy and growing investments in the development of advanced treatment methodologies is expected to fuel the progress of this market in the near future. The growth of the market can also be attributed to factors such as the increasing awareness regarding the development of human microbiome therapeutics by major market players and the rising occurrence of chronic diseases such as diabetes, cancer and neurological disorders on a global level. According to the International Diabetes Federation (IDF) data, approximately 463 million adults aged between 20-79 years were suffering from diabetes in 2019, and by 2045 the number is expected to increase to 700 million. Additionally, the rising initiatives by private organizations and government agencies to collaborate for the development of gut microbiome products are expected to offer ample growth opportunities to the global gut microbiota market over the forecast period.
Get more information on this report: Download Sample PDF
The market is segmented based on products into probiotics, prebiotics, supplements, drugs, foods, and others, out of which, the probiotics segment is anticipated to grab the largest share by the end of 2030 on account of increasing awareness regarding health & fitness among individuals and growing R&D activities to develop effective probiotics by major manufacturers in the market. Moreover, increasing focus and initiatives of regulatory bodies towards medical tourism globally are also expected to contribute to the development of the market segment in the upcoming years. Furthermore, on the basis of application, the therapeutics segment held the largest share in the global gut microbiota market on the back of growing investments for the development of microbiome-based therapies around the world.
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Geographically, the market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. The market in the Asia Pacific is expected to grow at the highest CAGR over the forecast period owing to the growing consciousness about gut microbiota therapies and rising prevalence of diabetes, cancer, cardiovascular diseases, and neurological disorders in the region. Furthermore, the market in North America is evaluated to hold the largest share in terms of revenue during the forecast period, on the back of growing government emphasis on the manufacture of premium quality gut microbiome products, accompanied by the presence of leading service providers in the region. Alternatively, the market in Europe is also anticipated to occupy a significant share in the global gut microbiota market on account of its proven success in terms of therapy development and a high occurrence of chronic diseases in the region. As per the Organisation for Economic Cooperation and Development (OECD) analysis, approximately 32.3 million adults in the European Union were diagnosed with diabetes in the year 2019.
Get more information on this report: Download Sample PDF
The global gut microbiota market is further classified on the basis of region as follows:
Our in-depth analysis of the global gut microbiota market includes the following segments:
FREQUENTLY ASKED QUESTIONS
Rising developments in gut microbiome therapeutics and increasing prevalence of chronic disorders in the world are the key factors driving market growth.
The market is anticipated to attain a ~23% CAGR over the forecast period, i.e., 2022-2030.
Poor understanding of gut microbiome products in under-developed countries is estimated to hamper market growth.
The market in Asia Pacific region will provide ample growth opportunities owing to the increasing awareness about gut microbiota therapeutics.
The major players dominating the gut microbiota market are ViThera Pharmaceuticals, Inc., Enterome SA, Ferring B.V., Second Genome, Synlogic Inc, and others.
The company profiles are selected on the basis of revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by products, applications, indications, and by region.
With respect to application, the therapeutics segment is anticipated to hold the largest market share owing to the growing investments by governmental agencies and leading market players for the development of new gut microbiome therapies.
Related Reports
Disclaimer | Privacy Policy | Terms & Conditions
Copyright © 2021 Research Nester. All Rights Reserved
